Stereochemistry | ACHIRAL |
Molecular Formula | C22H28N2O |
Molecular Weight | 336.4705 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C3=CC=CC=C3
InChI
InChIKey=PJMPHNIQZUBGLI-UHFFFAOYSA-N
InChI=1S/C22H28N2O/c1-2-22(25)24(20-11-7-4-8-12-20)21-14-17-23(18-15-21)16-13-19-9-5-3-6-10-19/h3-12,21H,2,13-18H2,1H3
Molecular Formula | C22H28N2O |
Molecular Weight | 336.4705 |
Charge | 0 |
Count |
MOL RATIO
1 MOL RATIO (average) |
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Fentanyl is a potent agonist of mu opioid receptor. It is used to relieve severe pain, such as after surgery or during cancer treatment, and breakthrough pain (flare-ups of intense pain despite round-the-clock narcotic treatment). Fentanyl is an extremely powerful analgesic, 50–100-times more potent than morphine. Fentanyl harbors massive risk for addiction and abuse regardless of its prescription form. Fentanyl abuse is especially dangerous to those without a tolerance to opioids. The substance’s already elevated risk of overdose is multiplied when someone without a tolerance abuses it.
CNS Activity
Originator
Approval Year
Doses
AEs
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Drug as perpetrator
Drug as victim
Tox targets
Sourcing
Sample Use Guides
Dosage should be individualized. Some of the factors to be considered in determining the dose are age, body weight,
physical status, underlying pathological condition, use of other drugs, type of anesthesia to be used and the surgical
procedure involved. Dosage should be reduced in elderly or debilitated patients (see PRECAUTIONS).
Vital signs should be monitored routinely.
I. Premedication — Premedication (to be appropriately modified in the elderly, debilitated and those who
have received other depressant drugs) — 50 to 100 mcg (0.05 to 0.1 mg) (1 to 2 mL) may be
administered intramuscularly 30 to 60 minutes prior to surgery.
II. Adjunct to General Anesthesia — See Dosage Range Chart
III. Adjunct to Regional Anesthesia - 50 to 100 mcg (0.05 to 0.1 mg) (1 to 2 mL) may be administered
intramuscularly or slowly intravenously, over one to two minutes, when additional analgesia is
required.
IV. Postoperatively (recovery room) - 50 to 100 mcg (0.05 to 0.1 mg) (1 to 2 mL) may be administered
intramuscularly for the control of pain, tachypnea and emergence delirium. The dose may be repeated
in one to two hours as needed
Route of Administration:
Other